Last reviewed · How we verify
Placebo - weeks 24 - 48
This drug has no known mechanism of action.
At a glance
| Generic name | Placebo - weeks 24 - 48 |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) (PHASE2)
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (PHASE2, PHASE3)
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
- A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy (PHASE2, PHASE3)
- Efficacy, Safety, and Tolerability of DYNE-101 in Participants With Myotonic Dystrophy Type 1 (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) (PHASE2)
- Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |